Adma Biologics Inc Денежные средства на акцию
Что обозначает Денежные средства на акцию в Adma Biologics Inc?
Денежные средства на акцию Adma Biologics Inc является 1.25
Какое определение для Денежные средства на акцию?
Денежные средства на акцию - это наличные денежные средства компании, поделенные на акции компании в обращении.
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
Денежные средства на акцию компаний в Health Care сектор на NASDAQ по сравнению с Adma Biologics Inc
Что делает Adma Biologics Inc?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Компании с денежные средства на акцию похож на Adma Biologics Inc
- Yatsen Ltd имеет Денежные средства на акцию из 1.24
- Aarons Inc имеет Денежные средства на акцию из 1.24
- AvalonBay Communities имеет Денежные средства на акцию из 1.24
- Global Net Lease имеет Денежные средства на акцию из 1.24
- TAJGVK Hotels & Resorts имеет Денежные средства на акцию из 1.24
- Sihuan Pharmaceutical имеет Денежные средства на акцию из 1.24
- Adma Biologics Inc имеет Денежные средства на акцию из 1.25
- Nagreeka Exports имеет Денежные средства на акцию из 1.25
- DENTSPLY Sirona Inc имеет Денежные средства на акцию из 1.25
- Kite Realty Trust имеет Денежные средства на акцию из 1.25
- J. C. Penney имеет Денежные средства на акцию из 1.25
- Bridgford Foods имеет Денежные средства на акцию из 1.25
- Stratec SE имеет Денежные средства на акцию из 1.25